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Abstract 
All cells contain proteases which effect catalytic hydrolysis of the peptide bond between amino 
acids in the protein backbone. Typically, proteinases are prevented from non-specific proteolysis 
by regulation and physical separation into different sub-cellular compartments; however, this 
segregation is not retained during cell lysis to release a protein of interest. Prevention of 
proteolysis during protein purification often takes the form of a two-pronged approach; firstly 
inhibition of proteolysis in situ, followed by the separation of the protease from the protein of 
interest via chromatographical purification. Proteinase inhibitors are routinely used to limit the 
effect of the proteinases before they are physically separated from the protein of interest via 
column chromatography. Here, commonly used approaches to reducing proteolysis during 
chromatography are reviewed. 
 
Key Words 
Protease, Proteolysis, Proteinase Inhibitor Buffer, Protein Purification. 
 
 
1. Introduction 
Protein stability can be defined as “the persistence of molecular integrity or biological function 
despite adverse influences or conditions, such as heat or other deleterious conditions” (1). One 
of the key deleterious conditions during protein chromatography is the presence of proteolytic 
substances, often referred to as proteases. Proteolysis is the directed degradation of proteins by 
specific proteases. Proteases have been referred to as “Nature’s Swiss Army knife” due to their 
diverse applications in protein cleavage (2). Proteases belong to the hydrolase class of enzyme 
(Enzyme Classification 3.4) which catalyse the hydrolysis of various bonds with the participation 
of a water molecule.The proteolytic process involves the hydrolysis of the peptide bonds that 
link amino acids together in the polypeptide chain. Proteases are defined as either exopeptidases 
(detach the terminal amino acids from the protein chain, examples include aminopeptidases and 
carboxypeptidase), or endopeptidases (which target internal peptide bonds of a protein, common 
examples here include trypsin, chymotrypsin, pepsin, and papain) (3). Proteases are also divided 
into four major groups according to their catalytic active site and mode of action: serine 
proteinases, cysteine (thiol) proteinases, aspartic proteinases, and metalloproteinases (4).  
Serine proteases, as the name suggests, have a serine residue as part of its catalytic site. 
Subtilisin (EC 3.4.21.62, an endopeptidase sourced from Bacillus subtilis) is one of the most 
common serine proteases examples cited (5). Cysteine proteases have a nucleophilic cysteine 
thiol as part of their active site. Papain (EC 3.4.22.2, an endopeptidase sourced from Carica 
papaya) is a frequently cited example of a cysteine protease (6). Aspartic proteinases use an 
aspartate residue for catalysis and, in general, they have two highly-conserved aspartate residues 
in the active site and are optimally active at acidic pH. Plasmepsin (EC 3.4.23.39, an 
endopeptidase produced by the Plasmodium parasite) is an example of an aspartic proteinase (7). 
Metalloproteinases contain a catalytic mechanism involving a metal; most contain zinc, however, 
cobalt centres are also observed. Adamalysin (EC 3.4.24.46, an endopeptidase from the 
rattlesnake Crotalus adamanteus) is an example of a metalloproteinase (8). 
 
Proteases are employed by all living cells to maintain a particular rate of protein turnover by 
continuous degradation and synthesis of proteins. Catabolism of proteins provides a ready pool 
of amino acids that can be reused as precursors for protein synthesis. Intracellular proteases 
participate in executing correct protein turnover for the cell: in E. coli, the ATP-dependent 
protease La, the lon gene product, is responsible for hydrolysis of abnormal proteins (9). The 
turnover of intracellular proteins in eukaryotes is also affected by a pathway involving ATP-
dependent proteases (10). 
As such, proteases are essential components in all life forms and in normal circumstances 
proteases are typically packaged into specialised organelles to minimise the chance of non-
specific proteolytic activity. Within these organelles there are specific regulators associated with 
each protease, controlling the action of the protease. However, when cells are disrupted for 
chromatography purification, proteases that are normally located in a different sub-cellular 
compartment are separated from their regulator molecules and exposed to the protein of interest, 
thus increasing the probability of undesired proteolysis (11). Realistically, it is impossible to 
remove all proteinases present in a chromatography sample preparation, however, careful 
selection of host cell (if protein of choice is recombinantly expressed) or cell type (if the protein 
of choice is native) in conjunction with specific sample preparation protocols can reduce 
unwanted proteolysis during purification (3).  
Proteases are ubiquitous and play a crucial role in normal and abnormal physiological conditions 
in all living things by effecting catalysis throughout many metabolic pathways. However, there is 
an uneven distribution of proteinases depending on which cell type (bacterial or eukaryotic) or 
tissue is disrupted. During heterologous protein expression, the recombinant protein of interest 
may be exposed to a host proteinase to which it is particularly susceptible. Simply altering the 
host may reduce recombinant proteolysis. Many commercial companies offer protease deficient 
strains for heterologous protein expression; for example E. coli BL21, is deficient in two 
proteases encoded by the lon (cytoplasmic protease) and ompT (periplasmic protease) genes (see 
Table 1). Additionally in mammalian tissues, liver and kidney samples contain a much higher 
concentration of proteolytic enzymes compared to skeletal or cardiac muscle (12). Once the 
source of the protein of choice has been optimized, a commonly used approach toward 
prevention of further unwanted proteolysis during protein isolation is to include proteinase 
inhibitors during sample preparation, purification, and characterization. 
 
INSERT TABLE ONE ABOUT HERE 
 
1.1 Proteinase Inhibitor Selection and Preparation. 
Judicious inhibitor choice will depend on the correct empirical identification of the proteinase 
involved. Classification of the proteinase(s) can be carried out in several ways, however, the 
simplest method is to incubate the sample of choice with a single inhibitor from the group of 
inhibitors (Serine, Cysteine, Thiol etc.) listed in Table 2. The degree of proteolysis can be 
identified from Sodium Dodecyl Sulfate PolyAcrylamide Gel Electrophoresis (SDS PAGE) 
analysis of the protein sample post inhibitor incubation; increased protein band smearing on the 
gel or a change in expected protein size will indicate potential proteolysis. Proteolysis inhibition, 
indicated by a maintenance of correct protein size with no protein band smearing after a given 
incubation period with inhibitor, will permit the identification of a suitable inhibitor group for 
the sample preparation. Once the protease has been identified, individual inhibitors can be 
chosen from Table 2 or a typical general-use proteinase inhibitor mix can be prepared 
immediately before use from the stock concentrations outlined in Table 3. Proteinase inhibitor 
solutions must be correctly stored after they have been prepared. Aliquot the stock of inhibitor 
and store at the correct temperature (see Table 2) to maintain the properties of the inhibitor. 
Make small, single use aliquots to reduce the risk of stock contamination. Ensure that the 
proteinase inhibitor/inhibitor mix is combined with the cell sample prior to cell disruption. If the 
individual proteinase inhibitor/inhibitor mix is to be prepared fresh then it must be used within 
one hour of preparation.  
 
INSERT TABLE TWO ABOUT HERE. 
 
INSERT TABLE THREE ABOUT HERE. 
 
It should be noted that the generic proteinase inhibitor cocktail outlined here is not guaranteed to 
work in all circumstances. The success of any mix will depend on the correct empirical 
identification of the proteinase involved. 
 
1.2 Commercially available Universal Protease Inhibitor Mixes. 
There are several types of commercially available “Universal Proteinase Inhibitors” that may 
also be used (e.g. Complete Protease Inhibitor Cocktail Tablets, Roche Applied Science). 
Additionally, many companies offer inhibitor panels, such as the Protease Inhibitor Panel 
(Sigma Aldrich), which is a cost-effective method for personalized proteinase cocktail inhibitor 
generation (13). 
 
 
1.3 Supplementary Protease Inhibitor Components. 
Additional Inhibitors 
If a particular protease is dominant within a sample preparation the cocktail mix may be 
supplemented with additional specific proteinase inhibitors (12,14 - 21). Commonly used 
specific individual protease inhibitor components are outlined in Table 4.  
 
INSERT TABLE FOUR ABOUT HERE. 
 
Phosphatase inhibitors may be required also as many enzymes are activated by phosphorylation, 
hence dephosphorylation must be inhibited if enzyme activity is to be maintained. Again, an 
empirical approach is required to identify if a phosphatase inhibitor is required (see Section 1.1 
and Table 5). Protein phosphatases can be divided into two main groups: protein tyrosine 
phosphatases and protein serine/threonine phosphatases which remove phosphate from proteins 
(or peptides) containing phosphotyrosine or phosphoserine/phosphothreonine respectively (22). 
Inhibitors commonly used here include: p-Bromotetramisole, Cantharidin, Microcystin LR 
(Ser/Thr Protein Phosphatases and Alkaline Phosphatase L-Isozymes) and Imidazole, Sodium 
molybdate, Sodium orthovanadate, Sodium tartrate (Tyr Protein Phosphatases and Acid and 
Alkaline Phosphatases, see Table 5). There are also a number of commercially available 
Phosphatase Inhibitor Mastermixes (e.g. PhosphataseArrest™ Phosphatase Inhibitor Cocktail, 
Geno Technologies Ltd.). These are often supplied in convenient, ready-to-use 100X solutions 
that are simply added to the protein extraction buffer or individual samples. These mixes can be 
sourced as either broad spectrum phosphatase inhibitor cocktails or as phosphatase inhibitors for 
targeting particular set of phosphatases. 
 
INSERT TABLE FIVE ABOUT HERE.  
 
1.4 Supplementary Chemical Compounds including Enzymes. 
The addition of supplementary chemical components to disrupt proteinase activity first should be 
carefully assessed on a small scale as often these components will alter the function/stability of 
the target protein (see Table 6). Furthermore, additional protease inhibitors should be introduced 
to the sample with caution as protein modifications, such as alteration of protein charge, may 
occur. These alterations may interfere with further protein characterisation studies. For example, 
2-mercaptoethanol will reduce the activity of cysteine proteinases, but will also unfold target 
proteins containing disulphide bridges. EDTA is included in many proteinase inhibitor buffers as 
metal ions are frequently involved in proteolysis, thus their removal will impede proteolysis. 
However, if one is purifying poly-Histidine tagged proteins or metalloproteins, then the chelating 
effect of EDTA will dramatically alter purification yields, and the EDTA should be removed 
from the buffer by dialysis or a buffer exchange resin. Inclusion of 2 M thiourea may also 
prevent proteolyis. Castellanos-Serra and Paz-Lago (23) noted the proteolysis inhibitory effects 
of its addition in conjunction with its efficiency in solubilizing proteins. DNase (100 U/mL), 
although not itself a protease inhibitor, can be included in the cell lysis buffer as this will reduce 
the overall viscosity of the crude lysate. The reaction is allowed to proceed for 10 min at 4°C in 
the presence of 10 mM MgCl2. 
 
INSERT TABLE SIX ABOUT HERE. 
 
1.5 Protease Inhibition During Chromatography. 
The introduction of contaminating proteases from your own skin, non-sterile water etc. can be 
avoided by sterilising all plasticware and by wearing appropriate personal protective equipment. 
All buffers should be sterile filtered (0.2 µm) into autoclaved bottles (sterile filtering will not 
remove contaminating proteases, but will remove any protease secreting microorganisms). 
Additionally, sterile filter the protein eluate once purification is complete.  
 
Cell disruption, as with all other parts of the purification procedure, should take place at 2-8oC. 
This temperature will not only reduce the activity of proteinases, but will also aid in stabilizing 
the target protein (reduction in thermal denaturation). Kulakowska-Bodzon and co-workers (24) 
provide an excellent review on protein preparation from various cell types for proteomic work. 
In general, all buffers and materials should be pre-chilled to 2-8oC. Rapid purification at this 
lower temperature will reduce the risk of unwanted proteolysis. Do not store such samples at 2-
8oC for more than one day between purification steps, instead store at -20°C. 
 
Gel filtration (size exclusion chromatography, see Chapter 2) is often used as the final step in 
protein purification and it can be used to desalt and buffer exchange the protein (therefore no 
need for dialysis). Contaminating proteinases can also be separated from the protein of choice if 
there is significant separation between elution peaks for the protease and the protein of choice. 
This is based on the presumption that there is a considerable difference between the size of the 
protease and the size of the protein of interest. 
 
1.6 Post Chromatography Analysis. 
Protease inhibition can be either reversible or irreversible. The majority of serine and cysteine 
proteinase inhibitors are irreversible, whereas the aspartic and metalloproteinase inhibitors are 
reversible. Even when the inhibitors are added at an early stage, they may be lost during 
purification and subsequent handling steps, resulting in proteolysis post-purification. The further 
re-addition of proteinase inhibitors may therefore be required after purification. 
 
Even with increased numbers of purification steps, very few protocols will remove all 
contaminants from a sample preparation however one can achieve an adequate reduction in the 
level of these contaminants. Each purification protocol will have a unique definition of 
“adequate protease reduction” based on a number of variables including the activity of the 
remaining proteases, further downstream applications of the protein of choice and the cost of 
further protease removal. Increased purification steps often result in a reduced final yield, as such 
the trade-off between contaminant reduction and yield must be optimised. A pure protein that 
gives a single band on a Coomassie-stained SDS-PAGE gel should be re-analysed over time to 
ensure minimal proteinase activity exists in the sample. This may be carried out by simply 
storing an aliquot of the purified protein solution at room temperature and analysing samples of 
this by SDS-PAGE at regular intervals. If the protein is being degraded (indicated by a smear or 
a reduced size of the protein of choice), proteinase contamination is present and an additional 
purification step (or supplemental inhibitor addition) is required. 
 
Some purification protocols require the addition of specific proteases such as enterokinase 
(recognition site D-D-D-K) or TEV protease (recognition site E-N-L-Y-F-Q-G) to remove 
polypeptide tags from recombinant proteins. Ensure that any proteinase inhibitor containing 
buffer is exchanged, by dialysis or a suitable buffer exchange resin, prior to the addition of the 
desired proteinase (see also Chapter 19).  
 
Care must be taken to rule out the possible loss of enzyme activity due to other destabilizing 
factors during protein purification. These other factors include, but are not limited to, thermal 
denaturation, oxidative damage and column surface adherence. Thermal denaturation of proteins 
is the decreased stability of a protein caused by extremes of temperature experienced by the 
protein of interest. Thermal denaturation can be reduced if the purification procedure is carried 
out at 2-8oC, all buffers and chromatography columns/resins are pre-chilled to 2-8oC and if the 
purified protein is stored at the correct temperature post-purification. Oxidative damage to 
proteins can be divided into a number of sections; however improper disulfide formation is the 
most pertinent here. Thiol oxidation is crucial for correct protein folding, resulting in a stabilized 
3-D protein structure in proteins containing disulphide bridges. The formation of incorrect intra- 
or intermolecular disulfides is a detrimental process that can often result in loss of activity and/or 
aggregation. Thiol oxidative damage can be avoided by not exposing the protein of choice to 
thiol reducing compounds (e.g. β-mercaptoethanol) during purification, thus maintaining the 
correct folded state of the protein. Column surface adherence is caused by the attraction of the 
protein of choice to the surface of the purification column by the protein’s intrinsic physico-
chemical properties (e.g. surface charge or hydrophobicity). Non-specific protein adherence can 
cause sheer stress damage to the protein during purification, however this can be circumvented 
by careful selection of the purification column (type/grade of glass or plastic) and purification 
resin. 
 
2.0 Conclusion. 
The presence of proteolytic enzymes can result in target protein degradation during protein 
chromatography. Careful selection of source organism/tissue, along with judicious use of 
protease inhibitors, can reduce these degrading effects. Commonly used inhibitors are listed here 
in tabular format (see Tables 3 and 4), along with supplemental compounds (see Tables 5 and 6) 
for easy selection. Protease inhibitors can be added individually or as part of a mix, however, 
optimal inhibitor selection is an empirical process. 
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Table 1: Some commercially available protease-deficient E. coli strains that are used to express 
recombinant proteins. 
Strain Name Protease Deficiency Supplier 
UT5600 Deficient in OmpT (an outer membrane protease that cleaves 
between sequential basic amino acids). 
New England Biolabs Inc. 
CAG626 
Deficient in Lon (a protease that 
degrades abnormal/misfolded 
proteins). 
New England Biolabs Inc. 
CAG597 Stress-induced proteases at high 
temperature. 
New England Biolabs Inc. 
CAG629 Stress-induced proteases at high 
temperature and Lon protease. 
New England Biolabs Inc. 
PR1031 Deficient in DnaJ –a chaperone that 
can promote protein degradation. 
New England Biolabs Inc. 
KS1000 Deficient in Prc (Tsp), a periplasmic 
protease. 
New England Biolabs Inc. 
Rosetta Deficient in Lon and OmpT. Novagen 
Rosetta-gami B Deficient in Lon and OmpT. Novagen 
Origami B Deficient in Lon and OmpT. Novagen 
BL21 Star
.
(DE3)pLysS 
Deficient in Lon and OmpT. Invitrogen 
BL21 Star
.
(DE3) 
Deficient in Lon and OmpT. Invitrogen 
BL21-AI Deficient in Lon and OmpT. Invitrogen 
 
 Table 2: Protease-Inhibitors: Stock Solutions and Storage Conditions. 
Inhibitor Activity Inhibitor Solvent Molarity Storage 
Serine PMSF1 dry methanol or propanol 200 mM -20oC 
Serine 3,4-DCL dimethylsulfoxide 10 mM -20oC 
Serine Benzamidine water 100 mM -20oC 
Cysteine Iodoacetic acid water 200 mM Prepare fresh 
Cysteine E64-c water 5 mM -20oC 
Thiol (serine & cysteine) Leupeptin water 10 mM -20oC 
Metallo 1,10 Phenanthroline methanol 100 mM RT3 or 4oC 
Metallo EDTA2 water 0.5 M RT3 or 4oC 
Acid Proteases Pepstatin DMSO 10 mM -20oC 
Aminopeptidase Bestatin water 5 mM -20oC 
 
1 PMSF is toxic. Weigh this compound in a fume hood, and wear appropriate personal protective 
equipment. 
2 Does not inhibit pancreatic elastase. 
3 RT - Room Temperature. 
 Table 3: General proteinase inhibitor mix 
Stock Inhibitor Volume (µL) 
PMSF (100 mM) or 3,4-DCI (10 mM) or Benzamidine (5 mM) 200 
Iodoacetate (200 mM) or E64-c (5 mM) 200 
1,10 phenanthroline (100 mM) or EDTA (500 mM) or Leupeptin (10 mM) 100 
Pepstatin (10 mM) 100 
Double Distilled Water 400 
Final Volume 1,000 
Table 4. Additional inhibitors that can be used to supplement protease inhibitor mixes. 
Inhibitor Solvent Molarity Storage 
Serine Protease Inhibitors    
Aprotinin (Does not inhibit thrombin or factor Xa) water 300 mM -20oC (at pH 7) 
Chymostatin (Inhibits chymotrypsin-like serine proteases 
such as chymase cathepsins A,B,D and G. Also inhibits 
some cysteine proteases such as papain) 
DMSO 10 mM -20oC 
Antithrombin III (Inhibits thrombin, kallikreins, plasmin, 
trypsin and factors Ixa, Xa, and Xia) 
water 10 Units/mL -20oC (at pH 7) 
TLCK (Inhibits chymotrypsin-like serine proteases) 1 mM HCl 100 µM Prepare fresh 
TPCK (Inhibits chymotrypsin-like serine proteases) Ethanol 10 mM 4oC 
DIFP (Highly toxic cholinesterase inhibitor. Broad 
spectrum serine protease inhibitor. Hydrolyzes rapidly in 
aqueous solutions) 
anhydrous 
isopropanol 
200 mM -20oC 
Antipain (Inhibits serine proteases such as plasmin, 
thrombin and trypsin. Also inhibits some cysteine 
proteases such as calpain and papain) 
water 10 mM -20oC 
α2-Macroglobulin (Broad spectrum protease inhibitor) water 100 mM -20oC 
    
Cysteine Protease Inhibitors    
N-Ethylmaleimide water 100 mM Prepare fresh 
    
Metalloproteinase Inhibitors    
Phosphoramidon (Strong inhibitor of 
metalloendoproteinases, thermolysin and elastases, but a 
week inhibitor of collagenase) 
water 1 mM -20oC 
 
 
Table 5: Commonly used phosphatase inhibitors. 
Name Typical Working Molarity Range Stock Molarity Typical Inhibitory Targets. 
p-Bromotetramisole 0.1 – 1.5 mM  100 mM Alkaline Phosphatases (25, 26) 
Cantharidin 20 – 250 µM 2.5 mM Protein Phosphatase 2-A (25, 27) 
Microcystin LR 20 – 250 nM 2.5 µM Protein Phosphatase 1 and 2-A 
(25, 28) 
Imidazole 50 – 200 mM 1 M Alkaline Phosphatases (29, 30) 
Sodium molybdate 50 – 125 mM 1 M Acid phosphatases and 
Phosphoprotein Phosphatases 
(27, 30) 
Sodium orthovanadate 50 – 100 mM 1 M ATPase inhibition, Protein 
Tyrosine Phosphatases, 
Phosphate-transferring enzymes. 
(30, 31) 
Sodium tartrate 50 – 100 mM 1 M Acid Phosphatases (28, 30). 
 
 
Table 6: Supplemental chemical/enzyme additions to protease inhibitor buffer (32). 
Item and typical working 
concentration 
Advantages Disadvantages Uses / Typical Protease 
Targets 
2-mercaptoethanol (1 mM) Reduction cysteine 
proteinase activity. 
Unfolding of target proteins 
containing disulphide 
bridges 
Cysteine Proteases 
EDTA  
(5 mM) 
Removal of metal ions 
involved in proteolysis 
impeding proteolysis 
The chelating effect of 
EDTA will affect the 
structure of metalloproteins 
and dramatically reduce the 
purification of poly-
Histidine tagged proteins. 
Non-His tagged protein 
targets or non-metalloprotein 
targets. 
Thiourea  
(2 M) 
Proteolysis inhibitory 
effects, in conjunction with 
improved protein 
solubilisation. 
Thiourea is considered a 
possible human carcinogen 
and mutagen. 
General purpose protease 
inhibitor. 
DNase  
(100 U/mL) 
Reduction in the crude lysate 
viscosity.  
Requires further incubation 
step of 10 min at 4°C in the 
presence of 10 mM MgCl2. 
Can be included in the cell 
lysis buffer for optimal 
efficiency. 
 
 
